<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878251</url>
  </required_header>
  <id_info>
    <org_study_id>K180106J</org_study_id>
    <secondary_id>2018-A00686-49</secondary_id>
    <nct_id>NCT03878251</nct_id>
  </id_info>
  <brief_title>Outcomes Measures in Intellectual Disability</brief_title>
  <acronym>EVALDI</acronym>
  <official_title>Development and Validation of Quantitative Attention Evaluation Criteria in Patients With Intellectual Disability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Plateforme PRISME</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective quantitative primary endpoints are lacking in Clinical trials in intellectual
      disability. We propose to develop quantitative interactive attention evaluation criteria in
      patients with intellectual disability by using games on touchscreen and or eye tracking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to develop and validate quantitative interactive attention evaluation
      criteria by using games on touchscreen and or eye tracking in patients with intellectual
      disability. Tests will have to be suitable whatever severity and etiology of intellectual
      disability. Tests have to evaluate attention and concentration troubles in intellectual
      disability.Once validated, tests could be used as outcome measures in clinical trials and as
      cognitive reeducation tools in intellectual disability.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between number of successful attempts and intellectual disability evaluated by Intelligence quotient (IQ) or age of development</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Test performed 1 time during a visit (1 day) can be repeated (for a maximum of 15 patients) within 3 months if an adaptation of the interactive tool is necessary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal reached level for each test</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of errors during the test</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach each level of the test</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum level of the test</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total test duration</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fixing time for eye tracking</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful test numbers in each level</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with Intelligence quotient (IQ) or age of development according to intellectual disability severity</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Attention Deficit in Intellectual Disability</condition>
  <arm_group>
    <arm_group_label>X fragile syndrome patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Angelman syndrome patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rett syndrome patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with other genetic rare syndromes with intellectual d</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Quantitative attention evaluation criteria in intellectual disability</intervention_name>
    <description>Quantitative interactive attention evaluation tests by using games on touchscreen and or eye tracking (oculometer)</description>
    <arm_group_label>Angelman syndrome patients</arm_group_label>
    <arm_group_label>Patients with other genetic rare syndromes with intellectual d</arm_group_label>
    <arm_group_label>Rett syndrome patients</arm_group_label>
    <arm_group_label>X fragile syndrome patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of both sex, with intellectual disability

          2. Minor patients 6 years old or more (age corresponding to the end of regression period
             observed in Rett patients) or major protected patients

          3. Patients with more or less severe intellectual disability from various causes
             including Fragile X syndrome, Rett syndrome, Angelman syndrome and other etiologies of
             intellectual disabilities and intellectual disabilities without identified etiology

          4. Affiliation to a social security system own or affiliated (excluding AME)

          5. Presence of parents or legal representative

          6. Informed consent signed by parents or legal representative

        Exclusion Criteria:

          1. Behavioral disorders not compatible with interactive tool (major agitation, straight
             and self aggressiveness)

          2. Uncontrolled seizure disorder despite treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CHARLES Perrine, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CHARLES Perrine, MD PhD</last_name>
    <phone>01 42 16 13 46</phone>
    <email>perrine.charles@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FAUDET Anne</last_name>
    <phone>01 42 16 13 46</phone>
    <email>anne.faudet@aphp.fr</email>
  </overall_contact_backup>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intellectual disability</keyword>
  <keyword>Attention evaluation criteria</keyword>
  <keyword>Games on touchscreen</keyword>
  <keyword>Eye tracking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intellectual Disability</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

